GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » ROC (Joel Greenblatt) %

Relypsa (Relypsa) ROC (Joel Greenblatt) % : -2,583.84% (As of Jun. 2016)


View and export this data going back to 2013. Start your Free Trial

What is Relypsa ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Relypsa's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2016 was -2,583.84%.

The historical rank and industry rank for Relypsa's ROC (Joel Greenblatt) % or its related term are showing as below:

RLYP's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -339.53
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Relypsa's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Relypsa ROC (Joel Greenblatt) % Historical Data

The historical data trend for Relypsa's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa ROC (Joel Greenblatt) % Chart

Relypsa Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
ROC (Joel Greenblatt) %
-3,969.98 -1,425.32 -1,282.06 -1,715.81 -2,703.09

Relypsa Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,706.38 -2,696.04 -2,548.98 -2,205.23 -2,583.84

Competitive Comparison of Relypsa's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Relypsa's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relypsa's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relypsa's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Relypsa's ROC (Joel Greenblatt) % falls into.



Relypsa ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.513 + 24.873 + 7.726) - (48.076 + 4.879 + 0)
=-19.843

Working Capital(Q: Jun. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.338 + 31.881 + 6.569) - (41.504 + 1.152 + 0)
=-2.868

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Relypsa for the quarter that ended in Jun. 2016 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2016 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2016  Q: Jun. 2016
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-263.332/( ( (10.089 + max(-19.843, 0)) + (10.294 + max(-2.868, 0)) )/ 2 )
=-263.332/( ( 10.089 + 10.294 )/ 2 )
=-263.332/10.1915
=-2,583.84 %

Note: The EBIT data used here is four times the quarterly (Jun. 2016) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Relypsa  (NAS:RLYP) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Relypsa ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Relypsa's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Relypsa (Relypsa) Business Description

Traded in Other Exchanges
N/A
Address
Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Executives
Ronald A. Krasnow officer: See Remarks C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball officer: Chief Financial Officer & SVP C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J director 33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl officer: SVP, Chief Technology Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland officer: SVP & Chief Commercial Officer 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley director C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi 10-26-2015